Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Rodrigo Yañez Gallardo*,"'
Publikováno v:
Revista de Psicología, Vol 36, Iss 1, Pp 135-162 (2018)
Research on interpersonal trust has been poorly analyzed from the conceptualization of Latin American workers. This research aimed to understand the meaning that health officials attribute to trust in direct leadership. A descriptive-analytical desig
Externí odkaz:
https://doaj.org/article/e335b34bcb1746c69b94fff79367f6c0
Publikováno v:
Revista Latino-Americana de Enfermagem, Vol 20, Iss 1, Pp 143-150 (2012)
Investigations show that distrust towards head figures has a particularly negative effect on organizational dynamics. Because of this, the main types of behavior associated with distrust in nursing professionals with leadership duties have been ident
Externí odkaz:
https://doaj.org/article/4b0e5f7a251945c4943a0c1c559f9b40
Publikováno v:
Liberabit, Vol 16 Nro. 2, Pp 193-202 (2010)
RESUMENSe evaluó el impacto de las relaciones interpersonales en el trabajo sobre la satisfacción laboral general. Primero, seconstruyó una escala para evaluar la satisfacción con las relaciones interpersonales en el trabajo y se aplicó a 209tra
Externí odkaz:
https://doaj.org/article/f185c4de51464b1b89b8e1247582cc97
Publikováno v:
Revista de Psicología; Vol. 36 Núm. 1 (2018); 135-162
Revistas Pontificia Universidad Católica del Perú
Pontificia Universidad Católica del Perú
instacron:PUCP
Revista de Psicología, Vol 36, Iss 1, Pp 135-162 (2018)
Revistas Pontificia Universidad Católica del Perú
Pontificia Universidad Católica del Perú
instacron:PUCP
Revista de Psicología, Vol 36, Iss 1, Pp 135-162 (2018)
Research on interpersonal trust has been poorly analyzed from the conceptualization of Latin American workers. This research aimed to understand the meaning that health officials attribute to trust in direct leadership. A descriptive-analytical desig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::b0d7f346c3df3a5ba47fbc51b580bab8
http://revistas.pucp.edu.pe/index.php/psicologia/article/view/19474
http://revistas.pucp.edu.pe/index.php/psicologia/article/view/19474
Autor:
Yañez-Gallardo, Rodrigo (AUTHOR), Valenzuela-Suazo, Sandra (AUTHOR)
Publikováno v:
Revista Latino-Americana de Enfermagem (RLAE). Jan/Feb2012, Vol. 20 Issue 1, p143-150. 8p.
Publikováno v:
Adunlin, G., Diaby, V., & Xiao, H. (2015). Application of multicriteria decision analysis in health care: A systematic review and bibliometric analysis. Health Expectations, 18(6), 1894–1905. https://doi.org/10.1111/hex.12287
Baltussen R. (2006). Priority setting of health interventions: The need for multi-criteria decision analysis. Cost Effetivennes and Resources Allocation, 1–9.
Belton, V., & Pictet, J. (1997). A framework for group decision using a mcda model: Sharing, aggregating, or comparing individual information? Journal of Decision Systems, 6(3), 283–303. https://doi.org/10.1080/12460125.1997.10511726
Bobo Zheng, Xin Wang, MingtianWei, QuanWang, Jiang Li, Liang Bi, X. D. and Z. W. (2019). First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: A systematic review and meta-analysis. BMC Cancer, 19, 280.
Bruno Rosa, J. P. de J. (s/f). Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: Systematic review and meta-analysis. ecancer, 9, 582.
Castro, H. E., Moreno-Mattar, O., & Rivillas, J. C. (2018). HTA and MCDA solely or combined? The case of priority-setting in Colombia. Cost Effectiveness and Resource Allocation: C/E, 16(Suppl 1), 47. https://doi.org/10.1186/s12962-018-0127-6
Castro Jaramillo, H. E., Goetghebeur, M., & Moreno-Mattar, O. (2016). Testing Multi-Criteria Decision Analysis for more Transparent Resource-Allocation Decision Making in Colombia. International Journal of Technology Assessment in Health Care, 32(4), 307–314. https://doi.org/10.1017/S0266462316000350
Catalize Ltd. (2010). Hiview3 Starter Guide. June 1–4. (2010). Catalize Ltda. http://www.catalyzeconsulting.com/software/hiview3/
Coplan, P. M., Noel, R. A., Levitan, B. S., Ferguson, J., & Mussen, F. (2011). Development of a framework for enhancing the transparency, reproducibility, and communication of the benefit-risk balance of medicines. 89(2), 312–315.
Daniels N. (2008). Accountability for reasonableness: An update. British Medical Journal, 1850.
Diaby, V., Campbell, K., & Goeree, R. (2013). Multi-criteria decision analysis (MCDA) in health care: A bibliometric analysis. Operations Research for Health Care, 2(1–2), 20–24. https://doi.org/10.1016/j.orhc.2013.03.001
Diaby V, L. J. (2011). An application of a proposed framework for formulary listing in low-income countries: The case of Cote d’Ivoire. Appl Health Econ Health Policy., 9(6), 389–402.
Dolan JG, B. DR. (1994). Isoniazid prophylaxis: The importance of individual values. Med Decis Making., 14(1), 1–8.
Dynamed Plus. (2018). Colorectal cancer: Overview and Recommendations (p. 97). DynaMed Plus.
E. Van Cutsem1, A. Cervantes2, B. Nordlinger3 & D. Arnold4, on behalf of the ESMO Guidelines Working Group*. (s/f). Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. 25 (Supplement 3): iii1–iii9, 2014. https://doi.org/doi:10.1093/annonc/mdu260
European Medicines Agency. (2020). Research and development. Human Regulatory. https://www.ema.europa.eu/en/human-regulatory/research-development
Filip Mussen, Sam Salek, Stuart Walker. (2007). A quantitative approach to benefit-risk assessment of medicines—Part 1: The development of a new model using multi-criteria decision analysis. jul 16, 2007, Supl;16 Suppl 1: S2-S15. https://doi.org/10.1002/pds.1435.
Gales C.E, M. JP. S. (1990). Searching for consensus through multi-criteria decision analysis. Assessment of screening strategies for hemoglobinopathies in southeastern FranceL. Int J Technol Assess Health Care, 6(3), 430–449.
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Akinyemiju, T. F., Al Lami, F. H., Alam, T., Alizadeh-Navaei, R., Allen, C., Alsharif, U., Alvis-Guzman, N., Amini, E., Anderson, B. O., Aremu, O., Artaman, A., Asgedom, S. W., Assadi, R., Atey, T. M., Avila-Burgos, L., Awasthi, A., Ba Saleem, H. O., … Naghavi, M. (2018). Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncology, 4(11), 1553–1568. https://doi.org/10.1001/jamaoncol.2018.2706
Goetghebeur, M. M., Wagner, M., Khoury, H., Levitt, R. J., Erickson, L. J., & Rindress, D. (2012). Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): Applying the evidem framework to medicines appraisal. Medical Decision Making, 32(2), 376–388. https://doi.org/10.1177/0272989X11416870
Goldstein, D. A., Chen, Q., Ayer, T., Chan, K. K. W., Virik, K., Hammerman, A., Brenner, B., Flowers, C. R., & Hall, P. S. (2017). Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis. The Oncologist, 22(6), 694–699. https://doi.org/10.1634/theoncologist.2016-0455
Hsu, J. C. (2019). Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment. PLOS ONE.
Hughes, D., St.mt, I., Chan, E., Downey, G., Hallgreen, C. E., Hockley, K. S., Juhaeri, J., Lieftucht, A., Metcalfe, M. A., Noel, R. A., Phillips, L., Ashby, D., & Micaleff, A. (2013a). IMI-PROTECT Benefit-Risk Group RECOMMENDATIONS REPORT. Recommendations for the methodology and visualization techniques to be used in the assessment of benefit and risk of medicines. Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium, 179.
Hughes, D., St.mt, I., Chan, E., Downey, G., Hallgreen, C. E., Hockley, K. S., Juhaeri, J., Lieftucht, A., Metcalfe, M. A., Noel, R. A., Phillips, L., Ashby, D., & Micaleff, A. (2013b). IMI-PROTECT Benefit-Risk Group RECOMMENDATIONS REPORT. Recommendations for the methodology and visualisation techniques to be used in the assessment of benefit and risk of medicines. Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium, 179.
Instituto de Evaluación Tecnológica en Salud (IETS). (2020). Protocolos. http://www.iets.org.co
Invima. (2019). Invima. https://www.invima.gov.co
International Agency for Research on Cancer. GLOBOCAN. (2018). International Agency for Research on Cancer. (http://gco.iarc.fr)
Marques, R. P. (2019). Patient‑reported outcomes and health‑related quality of life for cetuximab versus bevacizumab in metastatic colorectal cancer: A prospective cohort study. Journal of Cancer Research and Clinical Oncology, 145, 1719–1728.
Marsh, K. D., Sculpher, M., Caro, J. J., & Tervonen, T. (2018). The Use of MCDA in HTA: Great Potential, but More Effort Needed. Value in Health, 21(4), 394–397. https://doi.org/10.1016/j.jval.2017.10.001
Marsh, K., Lanitis, T., Neasham, D., Orfanos, P., & Caro, J. (2014). Assessing the value of healthcare interventions using multi-criteria decision analysis: A review of the literature. PharmacoEconomics, 32(4), 345–365. https://doi.org/10.1007/s40273-014-0135-0
McKenna, C., Soares, M., Claxton, K., Bojke, L., Griffin, S., Palmer, S., & Spackman, E. (2015). Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 18(6), 865–875. https://doi.org/10.1016/j.jval.2015.05.003
Mendoza-Sanchez, J., Silva, F., Rangel, Lady, Jaramillo, L., Mendoza, L., Garzon, J., & Quiroga, A. (2018). Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis. PLoS ONE, 13(5), 1–9. https://doi.org/10.1371/journal.pone.0196361
Molinari E, De Quatrebarbes J, Andre T, E. (2005). Cetuximab-induced acne. Dermatology, 211, 330–333.
Mt-Isa S, Hallgreen CE, Wang N, Callreus T, Genov G, Hirsch I, et al. Bs. (2014). Balancing benefit and risk of medicines: Drug, a systematic review and classification of available methodologies. Pharmacoepidemiol Drug, 23(7), 667-78.
NCCN, N. C. P. G. in O. for C. C. (2019). NCCN Clinical Practive Guidelines in Oncology for Colon Cancer. NCCN Clinical Practive Guidelines in Oncology for Colon Cancer (Vol. 90). https://doi.org/10.1007/978-1-4615-6165-1_18
Nixon, R., Dierig, C., Mt-Isa, S., Stöckert, I., Tong, T., Kuhls, S., Hodgson, G., Pears, J., Waddingham, E., Hockley, K., & Thomson. (2016). A case study using the PrOACT-URL and BRAT frameworks for structured benefit risk assessment. 58(1), 8–27.
OMS | Cáncer. (s/f). WHO; World Health Organization. Recuperado el 16 de septiembre de 2020, de http://www.who.int/topics/cancer/es/
Regulatory Education for Industry: Drug Registration and Listing Workshop-10/08/2020-10/08/2020. (2020, septiembre 10). FDA. https://www.fda.gov/drugs/news-events-human-drugs/regulatory-education-industry-drug-registration-and-listing-workshop-10082020-10082020
Rodrigo Yañez Gallardo. (S/F). La Técnica Delphi Y La Investigación En Los Servicios De Salud*. 2008, XIV (1), 9–15.
Rovira Forns, J. (2015). [Drug prices: How they are established and existing price control systems]. Salud Colectiva, 11(1), 35–48. https://doi.org/10.1590/S1851-82652015000100004
S, Stintzing, H. V. (2014). FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol.
Scartozzi M, Galizia E, Chiorrini S, E. (2009). Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol, 20, 227–230.
Sharma S. (s/f). How to calculate sample size for observational and experimental nursing research studies? 2019, 10(0), 1. https://doi.org/10.5455/njppp.2020.10.093071710201
Siegel RL. (2019). Cancer Statitcs. CA: A Cancer Journal for clinicians, 69(1), 7–34.
Thokala, P., Devlin, N., Marsh, K., Baltussen, R., Boysen, M., Kalo, Z., Longrenn, T., Mussen, F., Peacock, S., Watkins, J., & Ijzerman, M. (2016). Multiple criteria decision analysis for health care decision making—An introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value in Health, 19(1), 1–13. https://doi.org/10.1016/j.jval.2015.12.003
U.S Food and Drugs Administration. (2020). Drugs. Drugs. https://www.fda.gov/drugs
Venook, A. (2017a). Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial. JAMA, 317(23), 2392-2401.
Venook, A. (2017b). Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial. JAMA, 317(23), 2392-2401.
Volker H et al. (2016). A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
Volker Heinemann, S. S. (2015). Early tumour shrinkage (ETS) and depth of response colorectal cancer (mCRC). European Journal of Cancer. http://dx.doi.org/10.1016/j.ejca.2015.06.116
Wenstop F, M. P. (2001). Value focused rationality in AIDS policy. Health Policy, 57(1), 57–72.
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. The New England Journal of Medicine, 349(5), 427–434. https://doi.org/10.1056/NEJMoa021491
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Baltussen R. (2006). Priority setting of health interventions: The need for multi-criteria decision analysis. Cost Effetivennes and Resources Allocation, 1–9.
Belton, V., & Pictet, J. (1997). A framework for group decision using a mcda model: Sharing, aggregating, or comparing individual information? Journal of Decision Systems, 6(3), 283–303. https://doi.org/10.1080/12460125.1997.10511726
Bobo Zheng, Xin Wang, MingtianWei, QuanWang, Jiang Li, Liang Bi, X. D. and Z. W. (2019). First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: A systematic review and meta-analysis. BMC Cancer, 19, 280.
Bruno Rosa, J. P. de J. (s/f). Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: Systematic review and meta-analysis. ecancer, 9, 582.
Castro, H. E., Moreno-Mattar, O., & Rivillas, J. C. (2018). HTA and MCDA solely or combined? The case of priority-setting in Colombia. Cost Effectiveness and Resource Allocation: C/E, 16(Suppl 1), 47. https://doi.org/10.1186/s12962-018-0127-6
Castro Jaramillo, H. E., Goetghebeur, M., & Moreno-Mattar, O. (2016). Testing Multi-Criteria Decision Analysis for more Transparent Resource-Allocation Decision Making in Colombia. International Journal of Technology Assessment in Health Care, 32(4), 307–314. https://doi.org/10.1017/S0266462316000350
Catalize Ltd. (2010). Hiview3 Starter Guide. June 1–4. (2010). Catalize Ltda. http://www.catalyzeconsulting.com/software/hiview3/
Coplan, P. M., Noel, R. A., Levitan, B. S., Ferguson, J., & Mussen, F. (2011). Development of a framework for enhancing the transparency, reproducibility, and communication of the benefit-risk balance of medicines. 89(2), 312–315.
Daniels N. (2008). Accountability for reasonableness: An update. British Medical Journal, 1850.
Diaby, V., Campbell, K., & Goeree, R. (2013). Multi-criteria decision analysis (MCDA) in health care: A bibliometric analysis. Operations Research for Health Care, 2(1–2), 20–24. https://doi.org/10.1016/j.orhc.2013.03.001
Diaby V, L. J. (2011). An application of a proposed framework for formulary listing in low-income countries: The case of Cote d’Ivoire. Appl Health Econ Health Policy., 9(6), 389–402.
Dolan JG, B. DR. (1994). Isoniazid prophylaxis: The importance of individual values. Med Decis Making., 14(1), 1–8.
Dynamed Plus. (2018). Colorectal cancer: Overview and Recommendations (p. 97). DynaMed Plus.
E. Van Cutsem1, A. Cervantes2, B. Nordlinger3 & D. Arnold4, on behalf of the ESMO Guidelines Working Group*. (s/f). Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. 25 (Supplement 3): iii1–iii9, 2014. https://doi.org/doi:10.1093/annonc/mdu260
European Medicines Agency. (2020). Research and development. Human Regulatory. https://www.ema.europa.eu/en/human-regulatory/research-development
Filip Mussen, Sam Salek, Stuart Walker. (2007). A quantitative approach to benefit-risk assessment of medicines—Part 1: The development of a new model using multi-criteria decision analysis. jul 16, 2007, Supl;16 Suppl 1: S2-S15. https://doi.org/10.1002/pds.1435.
Gales C.E, M. JP. S. (1990). Searching for consensus through multi-criteria decision analysis. Assessment of screening strategies for hemoglobinopathies in southeastern FranceL. Int J Technol Assess Health Care, 6(3), 430–449.
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Akinyemiju, T. F., Al Lami, F. H., Alam, T., Alizadeh-Navaei, R., Allen, C., Alsharif, U., Alvis-Guzman, N., Amini, E., Anderson, B. O., Aremu, O., Artaman, A., Asgedom, S. W., Assadi, R., Atey, T. M., Avila-Burgos, L., Awasthi, A., Ba Saleem, H. O., … Naghavi, M. (2018). Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncology, 4(11), 1553–1568. https://doi.org/10.1001/jamaoncol.2018.2706
Goetghebeur, M. M., Wagner, M., Khoury, H., Levitt, R. J., Erickson, L. J., & Rindress, D. (2012). Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): Applying the evidem framework to medicines appraisal. Medical Decision Making, 32(2), 376–388. https://doi.org/10.1177/0272989X11416870
Goldstein, D. A., Chen, Q., Ayer, T., Chan, K. K. W., Virik, K., Hammerman, A., Brenner, B., Flowers, C. R., & Hall, P. S. (2017). Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis. The Oncologist, 22(6), 694–699. https://doi.org/10.1634/theoncologist.2016-0455
Hsu, J. C. (2019). Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment. PLOS ONE.
Hughes, D., St.mt, I., Chan, E., Downey, G., Hallgreen, C. E., Hockley, K. S., Juhaeri, J., Lieftucht, A., Metcalfe, M. A., Noel, R. A., Phillips, L., Ashby, D., & Micaleff, A. (2013a). IMI-PROTECT Benefit-Risk Group RECOMMENDATIONS REPORT. Recommendations for the methodology and visualization techniques to be used in the assessment of benefit and risk of medicines. Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium, 179.
Hughes, D., St.mt, I., Chan, E., Downey, G., Hallgreen, C. E., Hockley, K. S., Juhaeri, J., Lieftucht, A., Metcalfe, M. A., Noel, R. A., Phillips, L., Ashby, D., & Micaleff, A. (2013b). IMI-PROTECT Benefit-Risk Group RECOMMENDATIONS REPORT. Recommendations for the methodology and visualisation techniques to be used in the assessment of benefit and risk of medicines. Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium, 179.
Instituto de Evaluación Tecnológica en Salud (IETS). (2020). Protocolos. http://www.iets.org.co
Invima. (2019). Invima. https://www.invima.gov.co
International Agency for Research on Cancer. GLOBOCAN. (2018). International Agency for Research on Cancer. (http://gco.iarc.fr)
Marques, R. P. (2019). Patient‑reported outcomes and health‑related quality of life for cetuximab versus bevacizumab in metastatic colorectal cancer: A prospective cohort study. Journal of Cancer Research and Clinical Oncology, 145, 1719–1728.
Marsh, K. D., Sculpher, M., Caro, J. J., & Tervonen, T. (2018). The Use of MCDA in HTA: Great Potential, but More Effort Needed. Value in Health, 21(4), 394–397. https://doi.org/10.1016/j.jval.2017.10.001
Marsh, K., Lanitis, T., Neasham, D., Orfanos, P., & Caro, J. (2014). Assessing the value of healthcare interventions using multi-criteria decision analysis: A review of the literature. PharmacoEconomics, 32(4), 345–365. https://doi.org/10.1007/s40273-014-0135-0
McKenna, C., Soares, M., Claxton, K., Bojke, L., Griffin, S., Palmer, S., & Spackman, E. (2015). Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 18(6), 865–875. https://doi.org/10.1016/j.jval.2015.05.003
Mendoza-Sanchez, J., Silva, F., Rangel, Lady, Jaramillo, L., Mendoza, L., Garzon, J., & Quiroga, A. (2018). Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis. PLoS ONE, 13(5), 1–9. https://doi.org/10.1371/journal.pone.0196361
Molinari E, De Quatrebarbes J, Andre T, E. (2005). Cetuximab-induced acne. Dermatology, 211, 330–333.
Mt-Isa S, Hallgreen CE, Wang N, Callreus T, Genov G, Hirsch I, et al. Bs. (2014). Balancing benefit and risk of medicines: Drug, a systematic review and classification of available methodologies. Pharmacoepidemiol Drug, 23(7), 667-78.
NCCN, N. C. P. G. in O. for C. C. (2019). NCCN Clinical Practive Guidelines in Oncology for Colon Cancer. NCCN Clinical Practive Guidelines in Oncology for Colon Cancer (Vol. 90). https://doi.org/10.1007/978-1-4615-6165-1_18
Nixon, R., Dierig, C., Mt-Isa, S., Stöckert, I., Tong, T., Kuhls, S., Hodgson, G., Pears, J., Waddingham, E., Hockley, K., & Thomson. (2016). A case study using the PrOACT-URL and BRAT frameworks for structured benefit risk assessment. 58(1), 8–27.
OMS | Cáncer. (s/f). WHO; World Health Organization. Recuperado el 16 de septiembre de 2020, de http://www.who.int/topics/cancer/es/
Regulatory Education for Industry: Drug Registration and Listing Workshop-10/08/2020-10/08/2020. (2020, septiembre 10). FDA. https://www.fda.gov/drugs/news-events-human-drugs/regulatory-education-industry-drug-registration-and-listing-workshop-10082020-10082020
Rodrigo Yañez Gallardo. (S/F). La Técnica Delphi Y La Investigación En Los Servicios De Salud*. 2008, XIV (1), 9–15.
Rovira Forns, J. (2015). [Drug prices: How they are established and existing price control systems]. Salud Colectiva, 11(1), 35–48. https://doi.org/10.1590/S1851-82652015000100004
S, Stintzing, H. V. (2014). FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol.
Scartozzi M, Galizia E, Chiorrini S, E. (2009). Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol, 20, 227–230.
Sharma S. (s/f). How to calculate sample size for observational and experimental nursing research studies? 2019, 10(0), 1. https://doi.org/10.5455/njppp.2020.10.093071710201
Siegel RL. (2019). Cancer Statitcs. CA: A Cancer Journal for clinicians, 69(1), 7–34.
Thokala, P., Devlin, N., Marsh, K., Baltussen, R., Boysen, M., Kalo, Z., Longrenn, T., Mussen, F., Peacock, S., Watkins, J., & Ijzerman, M. (2016). Multiple criteria decision analysis for health care decision making—An introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value in Health, 19(1), 1–13. https://doi.org/10.1016/j.jval.2015.12.003
U.S Food and Drugs Administration. (2020). Drugs. Drugs. https://www.fda.gov/drugs
Venook, A. (2017a). Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial. JAMA, 317(23), 2392-2401.
Venook, A. (2017b). Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial. JAMA, 317(23), 2392-2401.
Volker H et al. (2016). A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
Volker Heinemann, S. S. (2015). Early tumour shrinkage (ETS) and depth of response colorectal cancer (mCRC). European Journal of Cancer. http://dx.doi.org/10.1016/j.ejca.2015.06.116
Wenstop F, M. P. (2001). Value focused rationality in AIDS policy. Health Policy, 57(1), 57–72.
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. The New England Journal of Medicine, 349(5), 427–434. https://doi.org/10.1056/NEJMoa021491
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
El cáncer colorrectal es una enfermedad común, 50-60% de los casos se presentan en estadios avanzados. Se ha observado una disminución en la mortalidad gracias al advenimiento de nuevas opciones de tratamiento entre las que encontramos las terapia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76c88feb6c8ab5ebc901c5c4f39ef993
https://repository.urosario.edu.co/handle/10336/31618
https://repository.urosario.edu.co/handle/10336/31618